Renaissance Capital logo

DICE Therapeutics Priced, Nasdaq: DICE

Phase 1-ready biotech developing oral small molecule therapies for immunologic diseases.

Industry: Health Care

Latest Trade: $33.25 0.00 (0.0%)

First Day Return: +117.0%

Return from IPO: +95.6%

Industry: Health Care

We are a biopharmaceutical company leveraging our proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. We are initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. Our platform, which we refer to as DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. We believe there is a significant unmet medical need for convenient oral therapies in chronic immunological diseases that offer the therapeutic benefits of systemic biologics. We are leveraging our proprietary DELSCAPE platform to design and develop a pipeline of wholly-owned oral small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas. In collaboration with Sanofi, we are also developing a therapeutic candidate for immuno-oncology indications.
more less
IPO News for DICE Therapeutics
more
IPO Data
IPO File Date 08/25/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 12.0
Deal Size ($mm) $204
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/14/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 12.0
Deal Size ($mm) $204
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2013
Employees 32
Website www.dicemolecules.com